利西拉来治疗2型糖尿病的有效性及安全性的Meta分析

中国临床药理学与治疗学 ›› 2015, Vol. 20 ›› Issue (2): 167-174.

利西拉来治疗2型糖尿病的有效性及安全性的Meta分析

伍艳¹, 吴翠芳², 汪江林²

¹长沙市望城区人民医院药剂科;
²中南大学湘雅三医院药学部,长沙 410013,湖南

收稿日期:2014-02-22 修回日期:2014-05-30 出版日期:2015-02-26 发布日期:2015-03-20
通讯作者: 汪江林,女,硕士研究生,研究方向:临床药学。Tel: 18774940040 E-mail: 524753872@qq.com
作者简介:伍艳,女,本科,副主任药师,主要从事临床药学工作。Tel: 13707319169 E-mail: 36179684@qq.com
基金资助:
国家自然科学基金资助项目(81102512);中南大学中央高校基本科研业务费专项基金资助项目(2014zzts316);新世纪优秀人才支持计划资助(NCET-13-0605)

Efficacy and safety of lixisenatide in comparison to placebo: a meta-analysis of randomized controlled trials

WU Yan¹, WU Cui-fang², WANG Jiang-lin²

¹Department of Pharmacy, the People's Hospital of Wangcheng District;
²Department of Parmacy, the Third Xiangya Hospital of Central South University, Changsha 410013, Hunan,China

Received:2014-02-22 Revised:2014-05-30 Online:2015-02-26 Published:2015-03-20

摘要/Abstract

摘要： 目的: 系统评价利西拉来与安慰剂比较治疗2型糖尿病的疗效和安全性。方法: 计算机检索PubMed、EMBASE、OVID、Cochrane、CNKI、VIP、CBM数据库,查找利西拉来与安慰剂比较治疗2型糖尿病的随机对照试验(randomized controlled trial,RCT),对纳入研究进行方法学质量评价,并用RevMan 5.2 软件进行Meta分析。通过Stata 12.0 软件对其是否对称按Begg's法进行分析,另外通过考察单项研究对总合并效应量的影响来进行敏感性分析,以评价结论的稳健性。结果: 共纳入8个RCT,随访时间≤24周的Meta分析结果显示:利西拉来在控制糖化血红蛋白(hemoglobin A1C,HbA1c)＜7%[RR=1.96,95%CI(1.65,2.32),P＜0.00001,Z=7.79]或≤6.5%[RR=2.70,95%CI(2.26,3.23),P＜0.00001,Z=10.83]的达标率方面均优于安慰剂组。总不良反应及低血糖、注射部位反应、胃肠道反应、恶心、呕吐、头晕的发生率与安慰剂组相比,利西拉来组均高于安慰剂。头痛、腹泻的发生率两组相似,无统计学差异。所有不良反应均较轻微,绝大多数患者可以耐受。随访时间为76周时,Meta分析结果显示:利西拉来在控制糖化血红蛋白＜7%[ RR=1.30,95%CI(1.12,1.51),P=0.0005,Z=3.49]或≤6.5%[ RR=1.41,95%CI(1.12,1.78),P=0.004,Z=2.89]的达标率方面均优于安慰剂组。总不良反应、注射部位反应、胃肠道反应、恶心、呕吐的发生率与安慰剂组相比,利西拉来组均高于安慰剂,而低血糖、腹泻两组无明显差异。结论: 利西拉来可以有效控制2型糖尿病患者血糖,利西拉来主要的不良反应是低血糖、注射部位反应、胃肠道反应、恶心、呕吐、头晕、头痛、腹泻,但不良反应较轻微,因此可以用来治疗2型糖尿病,但远期结果有待高质量、大样本、长期随访的临床研究予以验证。

关键词: 利西拉来, 2 型糖尿病, 随机对照试验, Meta分析

Abstract: AIM: To estimate the efficacy and tolerability of lixisenatide in comparison to placebo in the treatment of type 2 diabetes.METHODS: PubMed, EMBASE, OVID, Cochrane, CNKI, VIP, CBM were searched and randomized controlled trials (RCT) of lixisenatide vs. placebo in treating type 2 diabetes were collected. The quality of included randomized controlled trials (RCTs) was assessed and then analyzed by the software RevMan5.2. The potential publication bias was performed by Stata 12.0 soft. Sensitivity analyses were used in the treatment course.RESULTS: Eight RCTs were ultimately identified. The results of meta-analyses showed that the proportion of patients that achieved an HbA1c ＜7%or≤6.5% was significantly greater in lixisenatide group than that in placebo group, there was statistical significance. The number of total adverse events, hypoglycemia, injection sites reactions, gastrointestinal disorders, nausea, vomiting, dizziness events in lixisenatide group was significantly lower than that in control group, there was statistical significance. Most of the adverse events reported were mild to moderate in intensity.CONCLUSION: The results of meta-analyses indicate that lixisenatide treatment for type 2 diabetes is effective. The major adverse of lixisenatide were hypoglycemia, injection site reactions, gastrointestinal disorders, nausea, vomiting, dizziness, headache, diarrhea. Although it may increase the risk of the adverse events,which reported were mild to moderate in intensity, lixisenatide appears to be an effective treatment for type 2 diabetes and a long-term study in large scale with high quality is required to confirm its long-term outcomes.

Key words: lixisenatide, type 2 diabetes, randomized controlled trials, Meta-analysis

中图分类号:

R311

伍艳, 吴翠芳, 汪江林. 利西拉来治疗2型糖尿病的有效性及安全性的Meta分析[J]. 中国临床药理学与治疗学, 2015, 20(2): 167-174.

WU Yan, WU Cui-fang, WANG Jiang-lin. Efficacy and safety of lixisenatide in comparison to placebo: a meta-analysis of randomized controlled trials[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(2): 167-174.

参考文献

[1] American Diabetes Association.Standards of medical care in diabetes--2013[J].Diabetes Care, 2013, 36 Suppl 1: S11-S66.
[2] Alvarez GF, Mavros P, Nocea G,et al.Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study[J].Diabetes Obes Metab, 2008, 10 Suppl 1: 8-15.
[3] Nathan DM, Buse JB, Davidson MB,et al.Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes[J].Diabetes Care, 2009, 32(1): 193-203.
[4] Rodbard HW, Jellinger PS, Davidson JA,et al.Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control[J].Endocr Pract, 2009, 15(6): 540-559.
[5] Tews D, Werner U, Eckel J.Enhanced protection against cytokine- and fatty acid-induced apoptosis in pancreatic beta cells by combined treatment with glucagon-like peptide-1 receptor agonists and insulin analogues[J].Horm Metab Res, 2008, 40(3): 172-180.
[6] Werner U, Vandewalle B, Conte JK,et al.The GLP-1 receptor agonist AVE0010 improves GSIS, prevents lipotoxicity-induced insulin depletion and preserves beta-cell function in human pancreatic islets[J].Diabetes, 2008, 571: A3-A4.
[7] Haschke G, Haag-Diergarten S, Werner U,et al.The GLP-1 receptor agonist AVE0010 preserves beta cell function and insulin secretion after a 6 week treatment in male obese Zucker diabetic fatty rats - an isolated perfused pancreas study[J].Diabetologia, 2006, 491: 400-401.
[8] Thorkildsen C, Neve S, Larsen BD,et al.Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice[J].J Pharmacol Exp Ther, 2003, 307(2): 490-496.
[9] Moore MC, Werner U, Smith MS,et al.Effect of the glucagon-like peptide-1 receptor agonist lixisenatide on postprandial hepatic glucose metabolism in the conscious dog[J].Am J Physiol Endocrinol Metab, 2013,305(12):1473-1482.
[10]Elkinson S, Keating GM.Lixisenatide: first global approval[J].Drugs, 2013, 73(4): 383-391.
[11]Bolli GB, Munteanu M, Dotsenko S,et al.Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1)[J].Diabet Med, 2014,31(2):176-184.
[12]Ahren B, Leguizamo DA, Miossec P,et al.Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M)[J].Diabetes Care, 2013, 36(9): 2543-2550.
[13]Fonseca VA, Alvarado-Ruiz R, Raccah D,et al.Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)[J].Diabetes Care, 2012, 35(6): 1225-1231.
[14]Pinget M, Goldenberg R, Niemoeller E,et al.Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P)[J].Diabetes Obes Metab, 2013, 15(11): 1000-1007.
[15]Ratner RE, Rosenstock J, Boka G.Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial[J].Diabet Med, 2010, 27(9): 1024-1032.
[16]Riddle MC, Aronson R, Home P,et al.Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L)[J].Diabetes Care, 2013, 36(9): 2489-2496.
[17]Riddle MC, Forst T, Aronson R,et al.Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1)[J].Diabetes Care, 2013, 36(9): 2497-2503.
[18]Seino Y, Min KW, Niemoeller E,et al.Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)[J].Diabetes Obes Metab, 2012, 14(10): 910-917.
[19]Werner U, Haschke G, Herling AW,et al.Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes[J].Regul Pept, 2010, 164(2/3): 58-64.